NCT03183661 A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial
| NCT ID | NCT03183661 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Anterogen Co., Ltd. |
| Condition | Crohn Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 9 participants |
| Start Date | 2016-11-16 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 9 participants in total. It began in 2016-11-16 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-CD injection in phase 1 clinical trial (ALLO-ASC-CD-101) for 36 months.
Eligibility Criteria
Inclusion Criteria: 1. Subjects who are injected with ALLO-ASC-CD in phase 1 clinical trial of ALLO-ASC-CD-101. 2. Subjects who are able to give written informed consent prior to study start and to comply with the study requirements. Exclusion Criteria: 1\. Subjects who are considered not suitable for the study by the principal investigator.
Contact & Investigator
Jae Hee Cheon, Ph D
✉ GENIUSHEE@yuhs.acJae Hee Cheon, Ph D
PRINCIPAL INVESTIGATOR
Yonsei University
Frequently Asked Questions
Who can join the NCT03183661 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Crohn Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03183661 currently recruiting?
Yes, NCT03183661 is actively recruiting participants. Contact the research team at GENIUSHEE@yuhs.ac for enrollment information.
Where is the NCT03183661 trial being conducted?
This trial is being conducted at Seoul, South Korea, Seoul, South Korea.
Who is sponsoring the NCT03183661 clinical trial?
NCT03183661 is sponsored by Anterogen Co., Ltd.. The principal investigator is Jae Hee Cheon, Ph D at Yonsei University. The trial plans to enroll 9 participants.